Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | TLR7 | Q9NYK1 | 14/20 | 0.56 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.55 |
| ▸ | IL6 | P05231 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20210108 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2D6TLR7TLR8IL6 | |
| SCHEMBL20209842 | 0.97 | CYP3A4 (0.96) | CYP3A4CYP2D6TLR7TLR8IL6 | |
| SCHEMBL20210102 | 0.92 | CYP3A4 (1.00) | CYP3A4CYP2D6TLR7TLR8IL6 | |
| SCHEMBL20210103 | 0.92 | CYP3A4 (0.84) | CYP3A4CYP2D6TLR7TLR8IL6 | |
| SCHEMBL30220149 | 0.91 | CYP3A4 (1.00) | CYP3A4CYP2D6TLR7TLR8IL6 | |
| SCHEMBL20210107 | 0.91 | CYP3A4 (1.00) | CYP3A4CYP2D6TLR7TLR8IL6 | |
| Hydrochloric Acid SCHEMBL23234423 | 0.90 | CYP3A4 (0.98) | CYP3A4CYP2D6TLR7TLR8IL6 | |
| Hydrochloric Acid SCHEMBL23234422 | 0.90 | CYP3A4 (0.98) | CYP3A4CYP2D6TLR7TLR8IL6 | |
| SCHEMBL20210101 | 0.89 | CYP3A4 (1.00) | CYP3A4CYP2D6TLR7IL6 | |
| SCHEMBL21481653 | 0.88 | CYP3A4 (0.80) | CYP3A4CYP2D6TLR7TLR8IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380593-A1 | PYRAZOLO-HETEROARYL DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2021-12-09 | — | — | US | disclosed |
| US-20210380593-A1 | PYRAZOLO-HETEROARYL DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2021-12-09 | — | — | US | disclosed |
| US-11117898-B2 | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-09-14 | — | — | US | disclosed |
| US-11117898-B2 | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-09-14 | — | — | US | disclosed |
| EP-3546457-B1 | PYRAZOLO-HETEROARYL DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2021-07-14 | — | — | EP | disclosed |
| EP-3546457-B1 | PYRAZOLO-HETEROARYL DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2021-07-14 | — | — | EP | disclosed |
| US-20210115046-A1 | PYRAZOLO-HETEROARYL DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-04-22 | — | — | US | disclosed |
| US-20210115046-A1 | PYRAZOLO-HETEROARYL DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-04-22 | — | — | US | disclosed |
| WO-2019196918-A1 | FIVE-MEMBERED HETEROCYCLO-PYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 罗欣药业(上海)有限公司 | 2019-10-17 | — | — | WO | disclosed |
| EP-3546457-A1 | PYRAZOLO-HETEROARYL DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-10-02 | — | — | EP | disclosed |
| EP-3546457-A1 | PYRAZOLO-HETEROARYL DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018095426-A1 | PYRAZOLO-HETEROARYL DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115046-A1 | PYRAZOLO-HETEROARYL DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF | TLR7, TLR3, TLR4 | CYP3A4 113/4885CYP2D6 128/4885TLR7 1/4885 |
| US-11117898-B2 | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | TLR7, TLR3, TLR4 | CYP3A4 113/4885CYP2D6 128/4885TLR7 1/4885 |
| US-20210380593-A1 | PYRAZOLO-HETEROARYL DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF | TLR7, TLR3, TLR4 | CYP3A4 113/4885CYP2D6 128/4885TLR7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.